What’s the future of genetic diagnostics? Where do the commercialization opportunities exist? Now we know.

On June 22, the Ontario Genomics Institute and MaRS Future of MedicineTM jointly held “Dx2010: Markers to Markets” – a workshop focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.

The invitation-only event drew over 70 representatives from developing biotech firms, multinationals, legal firms, investment groups and government.

If you missed this event, we now have content from the workshop available to the public.

Video:

Presentations:
FDA’s approach to regulation of in vitro diagnostic tests
View more presentations from MaRS Discovery District.

MammaPrint: From Bench to Bedside
View more presentations from MaRS Discovery District.

Regulatory oversight of genetic testing in Canada: Health Canada perspective
View more presentations from MaRS Discovery District.

Novel biomarkers for diagnostics and drug R&D: What is industry looking for?
View more presentations from MaRS Discovery District.

We hope you will enjoy these insights from the leading edge of gene-based diagnostic development!

Stay tuned for more OGI/MaRS Future of MedicineTM joint events on additional commercialization topics going forward.

John McCulloch

John provides assistance to life sciences entrepreneurs in business strategy, management, intellectual property, financing and licensing. See more…